JP2024523429A - ウイルス感染の神経学的合併症の処置と予防のための新規化合物 - Google Patents

ウイルス感染の神経学的合併症の処置と予防のための新規化合物 Download PDF

Info

Publication number
JP2024523429A
JP2024523429A JP2023578116A JP2023578116A JP2024523429A JP 2024523429 A JP2024523429 A JP 2024523429A JP 2023578116 A JP2023578116 A JP 2023578116A JP 2023578116 A JP2023578116 A JP 2023578116A JP 2024523429 A JP2024523429 A JP 2024523429A
Authority
JP
Japan
Prior art keywords
use according
compound
metabolite
day
ophioglossum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523429A5 (cg-RX-API-DMAC7.html
Inventor
ドン,ユホン
Original Assignee
サンレーゲン ヘルスケア エージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンレーゲン ヘルスケア エージー filed Critical サンレーゲン ヘルスケア エージー
Publication of JP2024523429A publication Critical patent/JP2024523429A/ja
Publication of JP2024523429A5 publication Critical patent/JP2024523429A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2023578116A 2021-06-18 2022-06-17 ウイルス感染の神経学的合併症の処置と予防のための新規化合物 Pending JP2024523429A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21180462.0 2021-06-18
EP21180462 2021-06-18
PCT/EP2022/066548 WO2022263624A1 (en) 2021-06-18 2022-06-17 Novel compounds for the treatment and prevention of neurological complications of viral infections

Publications (2)

Publication Number Publication Date
JP2024523429A true JP2024523429A (ja) 2024-06-28
JP2024523429A5 JP2024523429A5 (cg-RX-API-DMAC7.html) 2025-06-23

Family

ID=76532115

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023578116A Pending JP2024523429A (ja) 2021-06-18 2022-06-17 ウイルス感染の神経学的合併症の処置と予防のための新規化合物

Country Status (6)

Country Link
US (1) US20240307339A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355316A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024523429A (cg-RX-API-DMAC7.html)
KR (1) KR20240022560A (cg-RX-API-DMAC7.html)
CN (1) CN117529311A (cg-RX-API-DMAC7.html)
WO (1) WO2022263624A1 (cg-RX-API-DMAC7.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019052629A1 (en) * 2017-09-12 2019-03-21 Sunregen Healthcare Ag LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT
JP2019518034A (ja) * 2016-06-08 2019-06-27 サンレーゲン ヘルスケア アーゲー 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用
US20200230099A1 (en) * 2017-03-02 2020-07-23 Dae Hwa Pharma. Co., Ltd. Stable Pharmaceutical Composition Comprising Zanamivir

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150125A (en) * 1977-09-30 1979-04-17 Abbott Laboratories Triglyceride ester of phosphonoacetic acid having antiviral activity
JP2000007581A (ja) * 1998-06-18 2000-01-11 Nippon Kayaku Co Ltd 抗ウイルススプレー剤
KR20120129898A (ko) * 2009-12-30 2012-11-28 베일러 리서치 인스티튜트 알츠하이머 질환 및 노화 뇌를 위한 보충대사 치료요법
CN104940589A (zh) * 2015-06-18 2015-09-30 王峰 治疗急性结膜炎的中药制剂及制法
WO2018159941A1 (ko) * 2017-03-02 2018-09-07 대화제약 주식회사 자나미비르를 포함하는 안정한 약제학적 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019518034A (ja) * 2016-06-08 2019-06-27 サンレーゲン ヘルスケア アーゲー 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用
US20200230099A1 (en) * 2017-03-02 2020-07-23 Dae Hwa Pharma. Co., Ltd. Stable Pharmaceutical Composition Comprising Zanamivir
WO2019052629A1 (en) * 2017-09-12 2019-03-21 Sunregen Healthcare Ag LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 61, JPN6026021699, 2020, pages 2475, ISSN: 0005875216 *

Also Published As

Publication number Publication date
WO2022263624A1 (en) 2022-12-22
KR20240022560A (ko) 2024-02-20
US20240307339A1 (en) 2024-09-19
CN117529311A (zh) 2024-02-06
EP4355316A1 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
CN102215857B (zh) 包含生姜提取物或姜烯酚的药物组合物
Zhang et al. Icariin enhances remyelination process after acute demyelination induced by cuprizone exposure
CA2688327A1 (en) Methods and compositions for stimulating cells
CN110300581B (zh) 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途
CN113301893A (zh) 神经性疾病的治疗
JP5836937B2 (ja) Hip/papまたはその誘導体の新規用途
US20230078820A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
JP7850416B2 (ja) 細胞外小胞に含まれるenamptの産生および使用
JP7383298B2 (ja) Tdp-43凝集阻害剤
Wu et al. Lipid droplets deposition in perihematoma tissue is associated with neurological dysfunction after intracerebral hemorrhage
CN104095849A (zh) 一个异黄酮衍生物的多靶点作用及其改善学习记忆用途
WO2024106716A1 (ko) 2'-푸코실락토오스를 포함하는 치매 개선 또는 치료용 조성물
Lee et al. The effects of Korean Red Ginseng-derived components on oligodendrocyte lineage cells: Distinct facilitatory roles of the non-saponin and saponin fractions, and Rb1, in proliferation, differentiation and myelination
US20240307339A1 (en) Novel compounds for the treatment and prevention of neurological complications of viral infections
US20240390377A1 (en) Composition for the prevention or treatment of neurodegenerative or motor neuron diseases comprising halofuginone as an active ingredient
US10188669B2 (en) Mitochondria-targeted antioxidants for treatment of age-related brain disorders
JP2024508839A (ja) エレウテロシドbを有効成分として含む脳神経炎症治療用薬学的組成物
Belayev et al. LAU-0901, a novel platelet-activating factor receptor antagonist, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat
JP2024505458A (ja) コリンエステラーゼ阻害剤および抗酸化剤を含む脳疾患を治療するための医薬組成物
KR102538278B1 (ko) 진토닌을 유효성분으로 포함하는 헌팅턴병 예방 또는 치료용 조성물
Lv et al. RvD1 Combined with Exercise Promotes Mitophagy and Reduces Neuronal Apoptosis in Mice After Intracerebral Hemorrhage via the BDNF/TrkB/PI3K/AKT Pathway
KR102761768B1 (ko) 헌팅턴병을 치료하기 위한 진세노사이드 m1의 용도
US20230201134A1 (en) Compositions for the management of demyelinating disorders
KR20250132696A (ko) 돈태반 추출물을 포함하는 뇌신경계 관련 우울증 예방, 개선 또는 치료용 조성물
TWI650121B (zh) 化合物用於製備Tau蛋白病變類疾病之醫藥組成物上之用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250613

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602